The new product, ARS Pharma’s EURneffy, is poised to become the first intranasal formulation of epinephrine to reach the market in the EU for emergency treatment of a life-threatening allergic ...

FMXIN002, also known as NS002, is a powder formulation of epinephrine nasal spray developed by Nasus Pharma based on its unique intranasal powder proprietary technology. The company believes that ...

An adrenaline rush is a colloquial expression about the feeling of exhilaration and heightened energy that is brought on by ...

ARS Pharmaceuticals, Inc.'s stock soared 25% on strong earnings. Learn about neffy's market potential, risks, and future growth prospects. Read more about SPRY stock here.

Key achievements to date include: ARS Pharma plans to initiate a Phase 2b clinical trial in the second quarter of 2025 to evaluate its intranasal epinephrine technology as a treatment for acute flares ...